US2021316010A1PendingUtilityA1
Drug delivery product, composition and system
Est. expiryAug 10, 2038(~12.1 yrs left)· nominal 20-yr term from priority
Inventors:Chia-Liang Cheng
A61K 47/643A61K 47/6923A61K 47/6929A61P 35/00
53
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A conjugate comprising (a) a nanodiamond; (b) human serum albumin (HSA) adhered on the surface of nanodiamond by physical adsorption; and (c) a drug molecule chemically linked to said human serum albumin, wherein said drug molecule has a therapeutic effect.
Claims
exact text as granted — not AI-modified1 . A conjugate comprising:
(a) a nanodiamond (b) human serum albumin (HSA) adhered on the surface of nanodiamond by physical adsorption; and (c) a drug molecule chemically linked to said human serum albumin, wherein said drug molecule has a therapeutic effect.
2 . A conjugate according to claim 1 , wherein said drug molecule is an anti-cancer drug molecule.
3 . A conjugate according to claim 2 , wherein the cancer is cancer of the lymph nodes, liver, lung, bone, kidney, brain, gastric, liver or colon tissues.
4 . A conjugate according to any one of the preceding claims, wherein the drug molecule is doxorubicin hydrochloride, C 27 H 29 NO 11 (DOX).
5 . A conjugate according to any one of claims 1 to 3 , wherein the drug molecule is Methotrexate C 20 H 22 N 8 O 5 (MTX).
6 . A conjugate according to any one of the preceding claims, wherein the nanodiamond has a size in the range of from 25 nm to 80 nm.
7 . A conjugate according to any one of the preceding claims, wherein the nanodiamond has a size in the range of from 35 nm to 65 nm.
8 . A conjugate according to any one of the preceding claims, wherein the nanodiamond has a size of about 50 nm.
9 . A pharmaceutical solution, comprising a plurality of a conjugates and a liquid carrier, wherein said conjugate comprises
(a) a nanodiamond; (b) human serum albumin (HSA) adhered on the surface of nanodiamond by physical adsorption; and (c) a drug molecule chemically linked to said human serum albumin, wherein said drug molecule has a therapeutic effect.
10 . A pharmaceutical solution according to claim 9 , wherein said drug molecule is an anti-cancer drug molecule.
11 . A pharmaceutical solution according to claim 9 or claim 10 , wherein the cancer is cancer of the lymph nodes, liver, lung, bone, kidney, brain, gastric, liver or colon tissues.
12 . A pharmaceutical solution according to any one of claims 9 to 11 , wherein the drug molecule is doxorubicin hydrochloride, C 27 H 29 NO 11 (DOX).
13 . A pharmaceutical solution according to any one of claims 9 to 11 , wherein the drug molecule is Methotrexate C 20 H 22 N 8 O 5 (MTX).
14 . A pharmaceutical solution according to any one of claims 9 to 13 , wherein the nanodiamond has a size in the range of from 25 nm to 80 nm.
15 . A pharmaceutical solution according to any one of claims 9 to 14 , wherein the nanodiamond has a size in the range of from 35 nm to 65 nm.
16 . A pharmaceutical solution according to any one any one of claims 9 to 15 , wherein the nanodiamond has a size of about 50 nm.
17 . The use of a conjugate for the manufacture of a medicament for the prevention or treatment of a subject, wherein said conjugate comprises:
(a) a nanodiamond (b) human serum albumin (HSA) adhered on the surface of nanodiamond by physical adsorption; and (c) a drug molecule chemically linked to said human serum albumin, wherein said drug molecule has a therapeutic effect.
18 . The use according to claim 17 , wherein said drug molecule is an anti-cancer drug molecule.
19 . The use according to claim 18 , wherein the cancer is cancer of the lymph nodes, liver, lung, bone, kidney, brain, gastric, liver or colon tissues.
20 . The use according to any one of claims 17 to 19 , wherein the drug molecule is doxorubicin hydrochloride, C 27 H 29 NO 11 (DOX).
21 . The use according to any one of claims 17 to 19 , wherein the drug molecule is Methotrexate C 20 H 22 N 8 O 5 (MTX).
22 . The use according to any one of claims 17 to 21 , wherein the nanodiamond has a size in the range of from 25 nm to 80 nm.
23 . The use according to any one of claims 17 to 22 , wherein the nanodiamond has a size in the range of from 35 nm to 65 nm.
24 . The use according to any one of claims 17 to 23 , wherein the nanodiamond has a size of about 50 nm.
25 . A method of providing therapeutic treatment to a subject in need thereof, said method including the step of delivering to the subject a therapeutic amount of the pharmaceutical solution, wherein said pharmaceutical solution, comprises a plurality of a conjugates and a liquid carrier, wherein said conjugate comprises
(a) a nanodiamond (b) human serum albumin (HSA) adhered on the surface of nanodiamond by physical adsorption; and (c) a drug molecule chemically linked to said human serum albumin, wherein said drug molecule has a therapeutic effect.
26 . A method according to claim 25 , wherein said drug molecule is an anti-cancer drug molecule.
27 . A method according to claim 26 , wherein the cancer is cancer of the lymph nodes, liver, lung, bone, kidney, brain, gastric, liver or colon tissues.
28 . A method according to any one of claims 25 to 27 , wherein the drug molecule is doxorubicin hydrochloride, C 27 H 29 NO 11 (DOX).
29 . A method according to any one of claims 25 to 27 , wherein the drug molecule is Methotrexate C 20 H 22 N 8 O 5 (MTX).
30 . A method according to any one of claims 25 to 29 , wherein the nanodiamond has a size in the range of from 25 nm to 80 nm.
31 . A method according to any one of claims 25 to 30 , wherein the nanodiamond has a size in the range of from 35 nm to 65 nm.
32 . A method according to any one of claims 25 to 31 , wherein the nanodiamond has a size of about 50 nm.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.